single post

single post

Current Diagnostic and Treatment Algorithm for Soft Tissue Sarcomas

Overview

Soft tissue sarcomas are a heterogeneous group of more than 50 rare malignant tumors arising from mesenchymal tissues, including fat, muscle, nerves, fibrous tissue, blood vessels, and deep dermal structures. They may occur throughout the body, most commonly in the extremities, but also in the trunk, head and neck region, and retroperitoneum.

Importance of Specialized Care

Due to their rarity and biological complexity, soft tissue sarcomas require management in specialized, high-volume sarcoma centers with dedicated multidisciplinary expertise. Clinical evidence demonstrates improved outcomes when patients are treated in experienced sarcoma units.

Within the INDID Telemedicine network, care is delivered through certified partner centers in Germany, offering advanced diagnostic workflows, organ- and limb-sparing surgical techniques, and multidisciplinary tumor board–based treatment planning.

A personalized, stage-adapted treatment strategy is central to sarcoma management and forms the basis of all therapeutic decisions.

Initial Diagnostic Workup and Staging

For most international patients, diagnostic workup and staging are initiated locally and completed in coordination with INDID Telemedicine, without the need for immediate travel to Germany.

Baseline assessment

  • Medical history, family history, and physical examination 
  • Laboratory tests: full blood count, liver and renal function tests

Pathology

  • Primary diagnostic method: core needle biopsy under image guidance 
  • Surgical biopsy only in selected cases 
  • Existing pathology reports are reviewed centrally 


If required,
tissue blocks (paraffin-embedded or frozen samples) may be re-evaluated in German reference pathology laboratories, particularly when local diagnostic resources, immunohistochemistry, or molecular testing are limited

Imaging

  • MRI of the primary tumor region (gold standard for local staging) 
  • CT thorax for detection of pulmonary metastases 
  • CT abdomen when clinically indicated (especially retroperitoneal tumors) 
  • MR angiography in selected extremity cases 


High-quality DICOM imaging is essential for accurate staging and treatment planning. In cases of suboptimal imaging quality, INDID Telemedicine coordinates repeat or supplementary imaging locally.

Multidisciplinary Treatment Planning

All cases are reviewed in sarcoma-specific multidisciplinary tumor boards at partner centers in Germany.

Treatment selection is based on:

  • Histological subtype 
  • Tumor grade 
  • Disease stage 
  • Anatomical location 
  • Resectability and functional considerations

 

Treatment Modalities

Surgery

Surgical resection with negative margins (R0 resection) is the cornerstone of curative treatment. Whenever oncologically safe, limb- and function-preserving surgical approaches are prioritized.

Systemic Therapy

Chemotherapy is used depending on histological subtype, tumor grade, and disease stage, either in the neoadjuvant, adjuvant, or palliative setting. Response varies significantly across sarcoma subtypes.

Targeted and molecular therapies are considered in selected subtypes based on tumor biology and current guideline recommendations.

Regional Therapy

Isolated limb perfusion (ILP) may be used in selected extremity sarcomas to achieve tumor downstaging and enable limb preservation. This highly specialized technique is performed only in experienced centers, including partner institutions such as the Mannheim Sarcoma Center of Mannheim University Center of Heidelbeg University under Prof. Jens Jakob.

Follow-Up Strategy

Follow-up is individualized according to histology, stage, and recurrence risk. A typical surveillance schedule includes:

  • Every 3 months for 2 years: clinical examination + MRI of primary site 
  • Every 6 months for 2 years: CT thorax 
  • Long-term follow-up: extended intervals up to 5–10 years depending on risk profile 


Follow-up care can be coordinated remotely via INDID Telemedicine, minimizing the need for repeated travel to Germany.

Key Strength of INDID Telemedicine Approach

INDID Telemedicine integrates:

  • Cross-border completion of diagnostic workup 
  • Centralized expert pathology review 
  • Multidisciplinary tumor board decision-making in Germany 
  • Modern multimodal and personalized treatment planning 
  • Structured long-term remote follow-up and monitoring 


This integrated model ensures timely access to German sarcoma expertise while reducing delays in diagnosis and treatment initiation and minimizing unnecessary international travel.

References

Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovée, J. V. M. G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., De Álava, E., DeLaney, T. F., … Casali, P. G. (2021). Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(11), 1344–1381. https://doi.org/10.1016/j.annonc.2021.07.006

Share this article :